AACR: AbbVie says mid-stage trial backs navitoclax in myelofibrosis
AbbVie’s BCL-2 inhibitor navitoclax has reported phase 2 results in a trial involving rare and hard-to-treat blood cancer myelofibrosis, eyeing an indication not addressed with […]
AbbVie’s BCL-2 inhibitor navitoclax has reported phase 2 results in a trial involving rare and hard-to-treat blood cancer myelofibrosis, eyeing an indication not addressed with […]
Shots: The P-III GLOW study evaluates Imbruvica + Venclexta/Venclyxto (I+V) vs chlorambucil + obinutuzumab (C+O) in 211 patients in a ratio (1:1) aged ≥65yrs. with […]
Shots: The P-III CLL14 trial assessing the efficacy & safety of a combined regimen of Venclyxto/Venclexta + obinutuzumab vs obinutuzumab and chlorambucil in 432 patients […]
Shots: Five-year data from P-III MURANO trial shows sustained PFS with Venclexta/Venclyxto + MabThera/Rituxan vs BR in patients with r/r CLL The data showed a […]
Combination therapies involving Roche and AbbVie’s cancer drug Venclexta have been formally approved by the FDA in acute myeloid leukaemia, following supportive data from late-stage […]
Shots: The approval is based on P-lll VIALE-A & VIALE-C studies and updated data from the P-Ib M14-358 and the P-I/II M14-387 studies. The P-III […]
Copyright © 2024 | WordPress Theme by MH Themes